{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:52:02Z","timestamp":1784328722044,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.neuropharm.2018.10.006","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T10:07:49Z","timestamp":1539079669000},"page":"115-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["THC and gabapentin interactions in a mouse neuropathic pain model"],"prefix":"10.1016","volume":"144","author":[{"given":"Nicholas","family":"Atwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherelle L.","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4314-7689","authenticated-orcid":false,"given":"Christopher W.","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.10.006_bib1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/clpt.2011.188","article-title":"Cannabinoid-opioid interaction in chronic pain","volume":"90","author":"Abrams","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/01.wnl.0000253187.66183.9c","article-title":"Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial","volume":"68","author":"Abrams","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bph.13337","article-title":"Actions of the dual FAAH\/MAGL inhibitor JZL195 in a murine neuropathic pain model","volume":"173","author":"Adamson Barnes","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.neuropharm.2013.12.018","article-title":"Actions of the dual FAAH\/MAGL inhibitor JZL195 in a murine inflammatory pain model","volume":"81","author":"Anderson","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S1474-4422(10)70143-5","article-title":"Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment","volume":"9","author":"Baron","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib1s","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","article-title":"A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man","volume":"33","author":"Bennett","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib2s","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1744-8069-10-26","article-title":"A simplified up-down method (SUDO) for measuring mechanical nociception in rodents using von Frey filaments","volume":"10","author":"Bonin","year":"2014","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.11607\/ofph.1274","article-title":"The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review","volume":"29","author":"Boychuk","year":"2015","journal-title":"J. Oral Facial Pain Headache"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neulet.2015.09.021","article-title":"Gabapentin attenuates neuropathic pain and improves nerve myelination after chronic sciatic constriction in rats","volume":"607","author":"C\u00e2mara","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib8","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1097\/j.pain.0000000000001051","article-title":"Cannabis constituent synergy in a mouse neuropathic pain model","volume":"158","author":"Casey","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1471-4159.2005.03263.x","article-title":"Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate","volume":"94","author":"Coderre","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ptr.2401","article-title":"Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved","volume":"22","author":"Comelli","year":"2008","journal-title":"Phytother Res."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib11","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1124\/jpet.103.062836","article-title":"3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1\/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects","volume":"310","author":"De Vry","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejphar.2004.03.051","article-title":"Pharmacological characterization of the chronic constriction injury model of neuropathic pain","volume":"491","author":"De Vry","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.biopsych.2014.04.009","article-title":"Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal","volume":"77","author":"Deng","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib14","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","article-title":"Recommendations for the pharmacological management of neuropathic pain: an overview and literature update","volume":"85","author":"Dworkin","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/npp.2008.120","article-title":"Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial","volume":"34","author":"Ellis","year":"2009","journal-title":"Neuropsychopharmacology: Offic. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/ddr.21300","article-title":"Antinociceptive interactions between meloxicam and gabapentin in neuropathic pain depend on the ratio used in combination in rats","volume":"77","author":"Espinosa-Juarez","year":"2016","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neuropharm.2016.12.008","article-title":"Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists","volume":"116","author":"Grenald","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ejp.752","article-title":"Analysis of the anti-allodynic effects of combination of a synthetic cannabinoid and a selective noradrenaline re-uptake inhibitor in nerve injury-induced neuropathic mice","volume":"20","author":"Gunduz","year":"2016","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2009.01.014","article-title":"Oral pregabalin reverses cold allodynia in two distinct models of peripheral neuropathic pain","volume":"605","author":"Gustafsson","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib20","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.neuropharm.2009.12.010","article-title":"Cannabinoid receptor-mediated antinociception with acetaminophen drug combinations in rats with neuropathic spinal cord injury pain","volume":"58","author":"Hama","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib21","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1055\/s-0042-106303","article-title":"Effects of delta-9-tetrahydrocannabinol and cannabidiol on cisplatin-induced neuropathy in mice","volume":"82","author":"Harris","year":"2016","journal-title":"Planta Med."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejphar.2008.09.004","article-title":"Multiplicative interactions to enhance gabapentin to treat neuropathic pain","volume":"598","author":"Hayashida","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib23","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.pain.2011.06.017","article-title":"A new definition of neuropathic pain","volume":"152","author":"Jensen","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib24","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/bph.13534","article-title":"Opioid and cannabinoid synergy in a mouse neuropathic pain model","volume":"173","author":"Kazantzis","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib25","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1111\/bph.13887","article-title":"Single and combined effects of Delta9 -tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain","volume":"174","author":"King","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/1744-8069-6-83","article-title":"Molecular basis for the dosing time-dependency of anti-allodynic effects of gabapentin in a mouse model of neuropathic pain","volume":"6","author":"Kusunose","year":"2010","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1037\/1064-1297.14.1.42","article-title":"Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy","volume":"14","author":"Lindner","year":"2006","journal-title":"Exp. Clin. Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bcpt.12567","article-title":"Antinociceptive interaction of tramadol with gabapentin in experimental mononeuropathic pain","volume":"119","author":"Miranda","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000370244","article-title":"Antinociceptive synergism of gabapentin and nortriptyline in mice with partial sciatic nerve ligation","volume":"95","author":"Miranda","year":"2015","journal-title":"Pharmacology"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10787-017-0308-5","article-title":"Antinociceptive interaction of gabapentin with minocycline in murine diabetic neuropathy","volume":"25","author":"Miranda","year":"2017","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1358\/mf.2008.30.6.1254247","article-title":"Synergistic antiallodynic interaction between gabapentin or carbamazepine and either benfotiamine or cyanocobalamin in neuropathic rats","volume":"30","author":"Mixcoatl-Zecuatl","year":"2008","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/M17-0155","article-title":"The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review","volume":"167","author":"Nugent","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib33","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.nurt.2009.08.002","article-title":"Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside","volume":"6","author":"Rahn","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104117","article-title":"An overview of drug combination analysis with isobolograms","volume":"319","author":"Tallarida","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib35","doi-asserted-by":"crossref","first-page":"E694","DOI":"10.1503\/cmaj.091414","article-title":"Smoked cannabis for chronic neuropathic pain: a randomized controlled trial","volume":"182","author":"Ware","year":"2010","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib36","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2018.10.006_bib37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejphar.2007.12.035","article-title":"Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception","volume":"584","author":"Williams","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.006_bib38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpain.2012.10.009","article-title":"Low-dose vaporized cannabis significantly improves neuropathic pain","volume":"14","author":"Wilsey","year":"2013","journal-title":"J. Pain"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818307779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818307779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T11:17:49Z","timestamp":1617621469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818307779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":40,"alternative-id":["S0028390818307779"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.10.006","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"THC and gabapentin interactions in a mouse neuropathic pain model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}